Please assess the completion status of the following clinical trial:

Trial Title: Study of SNX-5422 in TP53 Null Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed solid or hematological TP53 null type cancer.~* No more than 4 prior lines of systemic anti-cancer therapy.~* Males or non-pregnant, non-breastfeeding females 18 years-of-age or older.~* Karnofsky performance score 60~* Life expectancy of at least 3 months.~* Adequate baseline laboratory assessments~* Recovered from toxicities of previous anticancer therapy to CTCAE Grade ≤ 1 with the exception of alopecia.~Exclusion Criteria:~* Treatment with an investigational agent within 30 days prior to the first dose of SNX-5422 or planning to receive an investigational agent during the study.~* Treatment with other anticancer drugs within 28 days or 5 half-lives of anticancer therapy (whichever is shorter) is prohibited from 30 days prior to the first dose of SNX-5422 and throughout the study.~* Radiation treatment within 2 weeks.~* The need for treatment with medications with clinically relevant metabolism by the cytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or after administration of SNX-5422 (Appendix B).~* Appropriately corrected screening ECG QTc interval 470 msec for females, 450 msec for males.~* Currently receiving medications known to cause QT prolongation AND corrected QTc of 450 msec for females, 430 msec for males.~* Patients with chronic diarrhea of grade 2 or greater despite maximal medical management.~* Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.~* Gastrointestinal diseases that could alter the assessment of safety, including irritable bowel syndrome, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis.~* History of documented adrenal dysfunction not due to malignancy.~* Seropositive for human immunodeficiency virus (HIV) or hepatitis C virus (HCV).~* History of chronic liver disease.~* Active hepatitis A or B.~* Current alcohol dependence or drug abuse.~* Clinically significant glaucoma, retinitis pigmentosa, or macular degeneration.~* Other serious concurrent illness or medical condition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SNX-5422 (Type: EXPERIMENTAL): Open-label administration of SNX-5422 capsules to total 100 mg/m2 every other day for 21 days (total = 11 doses), followed by a 7-day drug-free period. Each treatment cycle will be 28 days. Subjects will repeat this 28-day schedule until the cancer progresses or the subject is unable to tolerate SNX-5422.

Based on this trial design, predict the completion outcome and termination type (if applicable).